BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24756062)

  • 1. Novel biomarkers in acute heart failure: MR-pro-adrenomedullin.
    Peacock WF
    Clin Chem Lab Med; 2014 Oct; 52(10):1433-5. PubMed ID: 24756062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
    Maisel A; Mueller C; Nowak R; Peacock WF; Landsberg JW; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand I; Ng L; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Terracciano G; Kremastinos D; Hartmann O; von Haehling S; Bergmann A; Morgenthaler NG; Anker SD
    J Am Coll Cardiol; 2010 May; 55(19):2062-76. PubMed ID: 20447528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of different biomarkers for cardiovascular death in unselected older patients in the emergency department.
    Bahrmann P; Christ M; Hofner B; Bahrmann A; Achenbach S; Sieber CC; Bertsch T
    Eur Heart J Acute Cardiovasc Care; 2016 Dec; 5(8):568-578. PubMed ID: 26483565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers and diagnostics in heart failure.
    Gaggin HK; Januzzi JL
    Biochim Biophys Acta; 2013 Dec; 1832(12):2442-50. PubMed ID: 23313577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
    Maisel A; Mueller C; Nowak RM; Peacock WF; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand I; Ng LL; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Hartmann O; Morgenthaler NG; Anker SD
    J Am Coll Cardiol; 2011 Aug; 58(10):1057-67. PubMed ID: 21867843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mid-regional pro-adrenomedullin in acute heart failure: a better biomarker or just another biomarker?
    Potocki M; Ziller R; Mueller C
    Curr Heart Fail Rep; 2012 Sep; 9(3):244-51. PubMed ID: 22733501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides.
    Morbach C; Marx A; Kaspar M; Güder G; Brenner S; Feldmann C; Störk S; Vollert JO; Ertl G; Angermann CE;
    Eur J Heart Fail; 2017 Sep; 19(9):1166-1175. PubMed ID: 28516504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.
    Fraty M; Velho G; Gand E; Fumeron F; Ragot S; Sosner P; Mohammedi K; Gellen B; Saulnier PJ; Halimi JM; Montaigne D; Ducrocq G; Rehman M; Marre M; Roussel R; Hadjadj S;
    Diabetologia; 2018 Dec; 61(12):2643-2653. PubMed ID: 30232509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction.
    Klip IT; Voors AA; Anker SD; Hillege HL; Struck J; Squire I; van Veldhuisen DJ; Dickstein K;
    Heart; 2011 Jun; 97(11):892-8. PubMed ID: 21415071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
    Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
    Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.
    Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
    J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure.
    Xue Y; Taub P; Iqbal N; Fard A; Clopton P; Maisel A
    Eur J Heart Fail; 2013 Dec; 15(12):1343-9. PubMed ID: 23887059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
    Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department.
    Bahrmann P; Bahrmann A; Hofner B; Christ M; Achenbach S; Sieber CC; Bertsch T
    Eur Heart J Acute Cardiovasc Care; 2015 Apr; 4(2):137-47. PubMed ID: 25002708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
    Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
    J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.
    Arfsten H; Goliasch G; Bartko PE; Prausmüller S; Spinka G; Cho A; Novak J; Haslacher H; Strunk G; Struck J; Hülsmann M; Pavo N
    Br J Clin Pharmacol; 2021 Mar; 87(3):916-924. PubMed ID: 32598074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pleural N-terminal pro-B-type natriuretic peptide, midregion pro-atrial natriuretic peptide and mid-region pro-adrenomedullin for the diagnosis of pleural effusions associated with cardiac failure.
    Porcel JM; Bielsa S; Morales-Rull JL; Civit C; Cao G; Light RW; Esquerda A
    Respirology; 2013 Apr; 18(3):540-5. PubMed ID: 23278975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
    Funke-Kaiser A; Havulinna AS; Zeller T; Appelbaum S; Jousilahti P; Vartiainen E; Blankenberg S; Sydow K; Salomaa V
    Ann Med; 2014 May; 46(3):155-62. PubMed ID: 24506434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term mortality risk in emergency department acute heart failure.
    Peacock WF; Nowak R; Christenson R; DiSomma S; Neath SX; Hartmann O; Mueller C; Ponikowski P; Möckel M; Hogan C; Wu AH; Richards M; Filippatos GS; Anand I; Ng LL; Daniels LB; Morgenthaler N; Anker SD; Maisel AS
    Acad Emerg Med; 2011 Sep; 18(9):947-58. PubMed ID: 21906204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism.
    Pedowska-Włoszek J; Kostrubiec M; Kurnicka K; Ciurzynski M; Palczewski P; Pruszczyk P
    Thromb Res; 2013 Nov; 132(5):506-10. PubMed ID: 24060192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.